Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials

Acta Psychiatrica Scandinavica

Volumn 134, Issue 5, 2016, Pages 385-398

  Zheng, W ^a   Xiang, Y T ^b,c   Xiang, Y Q ^b   Li, X B ^b   Ungvari, G S ^d,e   Chiu, H F K ^f   Correll, C U ^g,h  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c University of Macau   (Macao)

^d UNIVERSITY OF NOTRE DAME   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g ZUCKER HILLSIDE HOSPITAL   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

antipsychotic; meta analysis; metabolic abnormalities; topiramate; weight gain

Indexed keywords

CLOZAPINE; INSULIN; NEUROLEPTIC AGENT; TOPIRAMATE; TRIACYLGLYCEROL;

ARTICLE; ASTHENIA; BODY MASS; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CARBOHYDRATE METABOLISM; CHINESE; COCHRANE LIBRARY; CONSTIPATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; FATIGUE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MEDLINE; MEMORY DISORDER; MENTAL DISEASE; META ANALYSIS; NAUSEA AND VOMITING; NEGATIVE SYNDROME; PARESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84990247183     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12631     Document Type: Article

References (90)

1. Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66:1012–1015.
2. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010;71:1115–1124.
3. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014;16:505–524.
4. Muscatello MR, Bruno A, De Fazio P, Segura-Garcia C, Pandolfo G, Zoccali R. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opin Pharmacother 2014;15:2329–2345.
5. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 2010;43:122–129.
6. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54(Suppl):42–49; discussion 55-46.
7. Correll CU, Maayan L, Kane JM, De Hert M, Cohen D. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia-spectrum disorders: results from a meta-analysis of randomized controlled trials. J Clin Psychiatry 2016;77:e746–e756.
8. Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015;35:499–509.
9. Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009;23:157–162.
10. Veerman SR, Schulte PF, Begemann MJ, Engelsbel F, de Haan L. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry 2014;47:185–194.
11. Dewan VK. Re: weight change with antipsychotic use. Can J Psychiatry 2001;46:660.
12. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45:198.
13. Karslioglu EH, Karakilic H, Taner E, Cosar B. Topiramate-induced psychotic exacerbation: case report and review of literature. Int J Psychiatry Clin Pract 2007;11:285–290.
14. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002;63:1045.
15. Navarro V, Pons A, Romero A, Bernardo M. Topiramate for clozapine-induced seizures. A J Psychiatry 2001;158:968–969.
16. Schuler-Springorum M, Hebebrand J, Wehmeier PM, Remschmidt H. [Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 case reports]. Z Kinder Jugendpsychiatr Psychother 2002;30:51–58.
17. Wang CY. Topiramate-induced weight loss in schizophrenia: a case report (in Chinese). SiChuan Mental Health 2011;24:11.
18. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001;15:297–301.
19. Levy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14:e234–e239.
20. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001;16:186–190.
21. Cates ME, Feldman JM, Boggs AA, Woolley TW, Whaley NP. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Annals Pharmacotherapy 2008;42:505–510.
22. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002;24:1576–1584.
23. Tramontina S, Zeni CP, Pheula G, Rohde LA. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psychopharmacol 2007;17:129–134.
24. Vieta E, Sanchez-Moreno J, Goikolea JM et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004;24:374–378.
25. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82:115–117.
26. Jiang J. The control study of topiramate treatment in weight gain caused by olanzapine (in Chinese). China Modern Doctor 2013;51:78–80.
27. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28:169–175.
28. Muscatello MR, Bruno A, Pandolfo G et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2011;25:667–674.
29. Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010;118:218–223.
30. Nickel MK, Nickel C, Muehlbacher M et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25:211–217.
31. Rezaei V, Mohammadi MR, Ghanizadeh A et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1269–1272.
32. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009;19:539–545.
33. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009;70:765–766.
34. Choi YJ. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. Sci World J 2015;2015:970730.
35. Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother 2010;44:668–679.
36. Gierisch JM, Nieuwsma JA, Bradford DW et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:e424–e440.
37. Greg Deardorff O, Syed A, Ames CJ, Yaeger JS. Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder. Prim Care Companion CNS Disord 2014;16, doi: 10.4088/PCC.13l01598.
38. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520–1530.
39. Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 2013;33:90–94.
40. Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014;40:1385–1403.
41. Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM. Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol 2015;71:389–401.
42. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 2009;34:1929–1941.
43. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–269, W264.
44. Varadhan KK, Neal KR, Lobo DN. Safety and efficacy of antibiotics compared with appendicectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials. BMJ 2012;344:e2156.
45. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. UK: Wiley Online Library, 2008
46. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
47. Weng DL. The study of topiramate combined with olanzapine in acute schizophrenia (in Chinese). Med Innovation China 2011;08:25–26.
48. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
49. Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463(459).
50. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979;86:638–641.
51. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
52. Balshem H, Helfand M, Schunemann HJ et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–406.
53. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
54. Behdani F, Hebrani P, Rezaei Ardani A, Rafee E. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011;14:270–275.
55. Chen ZX, Xia ML, Xia WJ, Huang HG, Jin L. Topiramate for prevention of olanzapine associated weight gain (in Chinese). Modern Pract Med 2012;24:979–980.
56. Chengappa K, Kupfer DJ, Parepally H et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 2007;9:609–617.
57. Li B, Liu ZL, Zhou HS et al. Efficacy and safety of topiramate combined with clozapine in the treatment of schizophrenia (in Chinese). China J Health Psychol 2012;20:964–965.
58. Liu JJ. The efficacy of topiramate in the treatment of antipsychotic-induced weight gain and lipid disorders (in Chinese). Modern Pract Med 2011;23:665–667.
59. Yang B, Zhang YT, Ye LX. Effect of treatment with topiramate on risperidone-induced weight mass variation and plasma leptin levels (in Chinese). Chinese J Nervous Mental Dis 2013;39:331–334.
60. Yang Y, Yang DL. Effect of treatment with topiramate on olanzpine-induced weight gain (in Chinese). ZheJiang Clin Med J 2011;13:1263–1265.
61. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 2001;24:43–49.
62. Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses 2013;6:186–196.
63. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl 1):S3–S9.
64. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16:961–966.
65. Astrup A, Caterson I, Zelissen P et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658–1669.
66. Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? Am J Ther 2007;14:581–584.
67. Trikalinos TA, Churchill R, Ferri M et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004;57:1124–1130.
68. Dag E, Dag ZO, Baydas G et al. Effects of lamotrigine and topiramate on brain maturation and cognitive functions in offspring of pregnant rats – preliminary study. Adv Clin Exp Med 2014;23:691–698.
69. Rass O, Umbricht A, Bigelow GE, Strain EC, Johnson MW, Mintzer MZ. Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. Psychol Addict Behav 2015;29:237–246.
70. Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol 2015;2015:969182.
71. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205–219.
72. Baptista T, Zarate J, Joober R et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5:279–299.
73. Birt J. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 2003;15:49–58.
74. Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009;63:1743–1761.
75. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120:18–33.
76. Das C, Mendez G, Jagasia S, Labbate LA. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 2012;24:225–239.
77. Gierisch JM, Nieuwsma JA, Bradford DW et al. Interventions to improve cardiovascular risk factors in people with serious mental illness. Rockville, MD: Agency for Healthcare Research and Quality, 2013.
78. Hasnain M, Fredrickson SK, Vieweg WV. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J Psychopharmacol 2011;25:715–721.
79. Himmerich H, Schuld A, Pollmacher T. Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies. Psychiatr Prax 2004;31(Suppl 2):S233–S237.
80. Housel AK, Waterbury N, Argo TR. Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics? Issues Ment Health Nurs 2009;30:803–805.
81. Khan AY, Macaluso M, McHale RJ, Dahmen MM, Girrens K, Ali F. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. J Psychiatr Pract 2010;16:289–296.
82. Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 2013;22:457–479.
83. Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014b;40:1385–1403.
84. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011;71:377–382.
85. Klein DJ, Saldana SN. Review: metformin is effective at attenuating the metabolic risks associated with use of atypical antipsychotics. Evid Based Ment Health 2011;14:55.
86. Lee YJ, Jeong JH. A systematic review of metformin to limit weight-gain with atypical antipsychotics. J Clin Pharm Ther 2011;36:537–545.
87. McIntyre RS, Alsuwaidan M, Goldstein BI et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 2012;24:69–81.
88. Miller LJ. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Pharmacotherapy 2009;29:725–735.
89. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 2012;27:69–75.
90. Correll CU, Sikich L, Reeves G, Riddle M. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? A J Psychiatry 2013;170:947–952.